Temsirolimus was approved by the FDA in 2007 for the treatment of advanced renal cell carcinoma, a disease resistant to existing chemotherapies (IFN-α, IL-2) [3,38-40]. This evidence concerns the gene IL2 and hereditary clear cell renal cell carcinoma.